HCPLive

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD

Oct 5, 2026 · 0:10:29

Listen to Episode

✨ AI Summary

Denifanstat maintains acne control for 52 weeks.
Oral FASN inhibitor shows favorable long-term safety profile.
Results from an open-label extension trial in moderate to severe acne.

Guests on This Episode

researcher · 4 podcast appearances

More from HCPLive

Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites

Oct 12, 2026 · 0:03:18

Targeting Senescent Cells in Actinic Keratosis With RLS-1496

Oct 12, 2026 · 0:04:25

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

Oct 12, 2026 · 0:03:33

Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF

Oct 12, 2026 · 0:06:00

View all episodes →